Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

Part of paid clinical trials in Stanford, California.

Sponsor
Sandy Srinivas
Study ID
NCT00651482
Phase
PHASE2
Status
Terminated

Conditions

  • Kidney (Renal Cell) Cancer
  • Kidney Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To determine the safety and efficacy of the combination of bevacizumab and everolimus (RAD001) for the treatment of metastatic renal cell cancer

Key Dates

First listed
Apr 2, 2008
Start date
Aug 31, 2008
Status verified
Mar 2017
Primary completion
Mar 31, 2012
Completion
Mar 31, 2012

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab + RAD001 (everolimus)
    Study treatment, consisting of bevacizumab + everolimus, was administered as 28-day cycles Bevacizumab 10 mg/kg administered by IV infusion every 14 days (dose suspension permitted, dose reduction not permitted) Everolimus 10 mg daily was administered orally (dose reduction to 5 mg daily and then 5 mg every other day, was permitted as needed for toxicity or tolerability)

Primary Outcome Measure

Progression-free Survival (PFS) [ Time Frame: 24 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicineStanfordCalifornia94305-

Find similar trials in Stanford, CA

By research site
Stanford University School of Medicine· Stanford, CA

Related Studies